Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

NKarta Therapeutics

Main focus: Natural killer cells for cancer treatment

Company stage: Clinical

Diseases: Solid and haematological cancers

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:NKTX)

Location: South San Francisco, CA, USA



Partners: CRISPR Therapeutics

Nkarta Therapeutics focuses on the development of natural killer (NK)-based cellular therapies. The company has developed a proprietary manufacturing platform that enables enhanced persistence, expansion and activity of NK and CAR-NK products. The company entered into a technology license agreement with CRISPR Therapeutics, that allows Nkarta to genetically modify its CAR-NK cell products. Furthermore, Nkarta and CRISPR Therapeutics are co-developing two programmes, one CAR-NK programme targeting CD70 and one combined NK + T cell programme.


HashtagNKarta Therapeutics

Company: NKarta Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine